Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec 3;71(17):2247-55.
doi: 10.2165/11596680-000000000-00000.

Serotonergic anti-obesity agents: past experience and future prospects

Jason C G Halford  1 , Emma J Boyland, Clare L Lawton, John E Blundell, Joanne A Harrold
Affiliations
Review

Serotonergic anti-obesity agents: past experience and future prospects

Jason C G Halford et al. Drugs. .

Abstract

The role of serotonin (5-hydroxytryptamine) in appetite control is long established. Serotonergic manipulations reduce food intake in rodents in a manner consistent with satiety. In humans, drugs such as fenfluramine, dexfenfluramine and sibutramine all reduce energy intake, suppress hunger and enhance satiety. Effects on eating behaviour and subjective sensations of appetite are associated with the weight loss-inducing effects of these treatments. Currently, no appetite-suppressing drugs are approved specifically for the treatment of obesity. However, a new generation of serotonergic drugs have progressed through clinical development. The serotonin 5-HT(2C)-receptor selective agonist lorcaserin, a drug specifically developed to target satiety without producing the side effect profiles of its predecessors, has been shown to significantly reduce energy intake and body weight. The weight loss produced by lorcaserin appears modest, and behavioural effects, particularly its supposed satiety-enhancing effects, have yet to be characterized. The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies. It remains unclear if this drug produces any effects on appetite mediated by serotonin, or whether weight loss is produced largely through enhanced energy expenditure. Evidence indicates that tesofensine strengthens satiety, but behavioural specificity and psychological side effects remain an issue. The serotonergic system remains a viable target for anti-obesity treatment. In this review, we examine the limited behavioural data available on these two new CNS-acting appetite suppressants.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Obes Res. 2004 Dec;12(12):2023-30 - PubMed
    1. Int J Obes Relat Metab Disord. 1992 May;16(5):355-60 - PubMed
    1. Arch Intern Med. 2004 May 10;164(9):994-1003 - PubMed
    1. Psychopharmacology (Berl). 1997 Jun;131(3):264-70 - PubMed
    1. Physiol Behav. 2001 Nov-Dec;74(4-5):507-16 - PubMed

MeSH terms

-